Capricor Therapeutics Announces $4 Million Registered Direct Offering
SC&H Capital, an investment banking and advisory firm focused on middle market and growth companies, announced that it acted as the placement agent for Capricor Therapeutics, Inc. (NASDAQ: CAPR), in its recent $4 million registered direct offering.
Capricor entered into a Subscription Agreement with certain investors for the purchase and sale of 1,692,151 shares of common stock at a price of $2.40 per share and warrants to purchase up to 846,073 shares of common stock with an exercise price of $4.50 per share. The warrants will be exercisable six months and one day from the date of the closing of the offering and have a term of three years.
Capricor is a biotechnology company focused on the discovery, development, and commercialization of first-in-class therapeutics. The company’s lead programs target post myocardial infarction (heart attack), heart failure, and Duchenne muscular dystrophy.
Click here to read the official press release from Capricor.